Biotech · Private company

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Track this companyFree. Adds Juno Therapeutics, Inc., a Bristol-Myers Squibb Company to your Dealase workspace and tells you when its record changes.

Clinical trials2317 recruiting or active

Pipeline programs57From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline57

BendamustinePhase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
BMS-986353Phase 3 · Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
BMS-986393Phase 3 · Relapsed or Refractory Multiple Myeloma (RRMM)ClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 3 · Relapsed or Refractory Multiple Myeloma (RRMM)ClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 3 · Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
DaratumumabPhase 3 · Relapsed or Refractory Multiple Myeloma (RRMM)ClinicalTrials.gov · fetched Nov 12, 2026
DexamethasonePhase 3 · Relapsed or Refractory Multiple Myeloma (RRMM)ClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 3 · Relapsed or Refractory Multiple Myeloma (RRMM)ClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 3 · Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
IdelalisibPhase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
Liso-celPhase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
NintedanibPhase 3 · Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
PomalidomidePhase 3 · Relapsed or Refractory Multiple Myeloma (RRMM)ClinicalTrials.gov · fetched Nov 12, 2026
RituximabPhase 3 · Leukemia, Lymphocytic, Chronic, B-CellClinicalTrials.gov · fetched Nov 12, 2026
RituximabPhase 3 · Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
TocilizumabPhase 3 · Systemic SclerosisClinicalTrials.gov · fetched Nov 12, 2026
Arlocabtagene AutoleucelPhase 2 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
BMS-986353Phase 2 · Chronic Immune ThrombocytopeniaClinicalTrials.gov · fetched Nov 12, 2026
CC-97540Phase 2 · Lupus Erythematosus, SystemicClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 2 · Lupus Erythematosus, SystemicClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 2 · Chronic Immune ThrombocytopeniaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · Lupus Erythematosus, SystemicClinicalTrials.gov · fetched Nov 12, 2026
Fludarabine PhosphatePhase 2 · Chronic Immune ThrombocytopeniaClinicalTrials.gov · fetched Nov 12, 2026
Liso-celPhase 2 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
MethotrexatePhase 2 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
ProcarbazinePhase 2 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
RituximabPhase 2 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
TemozolomidePhase 2 · LymphomaClinicalTrials.gov · fetched Nov 12, 2026
AlnuctamabPhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
BMS-986393Phase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
BMS-986453Phase 1 · Relapsed and/or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
BMS-986515Phase 1 · Refractory Autoimmune DiseasesClinicalTrials.gov · fetched Nov 12, 2026
BMS-986527Phase 1 · Clear Cell Renal Cell Carcinoma (ccRCC)ClinicalTrials.gov · fetched Nov 12, 2026
CabozantinibPhase 1 · Clear Cell Renal Cell Carcinoma (ccRCC)ClinicalTrials.gov · fetched Nov 12, 2026
CC-97540Phase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
CC-97540Phase 1 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Refractory Autoimmune DiseasesClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Relapsed and/or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
DexamethasonePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
ElranatamabPhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Relapsed and/or Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Refractory Autoimmune DiseasesClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
IberdomidePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
MezigdomidePhase 1 · Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
NivolumabPhase 1 · Clear Cell Renal Cell Carcinoma (ccRCC)ClinicalTrials.gov · fetched Nov 12, 2026
TocilizumabPhase 1 · Systemic Lupus ErythematosusClinicalTrials.gov · fetched Nov 12, 2026
TocilizumabPhase 1 · Refractory Autoimmune DiseasesClinicalTrials.gov · fetched Nov 12, 2026
Lisocabtagene maraleucelFollicular LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Lisocabtagene maraleucelChronic Lymphocytic Leukemia (CLL)ClinicalTrials.gov · fetched Nov 12, 2026
Lisocabtagene maraleucelMantle Cell Lymphoma (MCL)ClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials23

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic SclerosisPHASE3 · NOT_YET_RECRUITING · started Feb 3, 2027ClinicalTrials.gov NCT07335562 · fetched Nov 12, 2026
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)PHASE1 · NOT_YET_RECRUITING · started Dec 31, 2026ClinicalTrials.gov NCT07848295 · fetched Nov 12, 2026
Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE)PHASE2 · NOT_YET_RECRUITING · started Aug 31, 2026ClinicalTrials.gov NCT07603557 · fetched Nov 12, 2026
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System LymphomaPHASE2 · RECRUITING · started Nov 6, 2025ClinicalTrials.gov NCT07015242 · fetched Nov 12, 2026
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesPHASE1 · RECRUITING · started Sep 4, 2025ClinicalTrials.gov NCT07115745 · fetched Nov 12, 2026
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 14, 2025ClinicalTrials.gov NCT07015983 · fetched Nov 12, 2026
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)PHASE3 · RECRUITING · started Mar 12, 2025ClinicalTrials.gov NCT06615479 · fetched Nov 12, 2026
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing SettingRECRUITING · started Feb 4, 2025ClinicalTrials.gov NCT06794268 · fetched Nov 12, 2026
A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRECRUITING · started Feb 4, 2025ClinicalTrials.gov NCT06788639 · fetched Nov 12, 2026
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing SettingRECRUITING · started Feb 4, 2025ClinicalTrials.gov NCT06788652 · fetched Nov 12, 2026
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)PHASE1 · ACTIVE_NOT_RECRUITING · started Mar 28, 2024ClinicalTrials.gov NCT06220201 · fetched Nov 12, 2026
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaPHASE2 · RECRUITING · started Mar 21, 2024ClinicalTrials.gov NCT06297226 · fetched Nov 12, 2026
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaPHASE1 · RECRUITING · started Feb 22, 2024ClinicalTrials.gov NCT06121843 · fetched Nov 12, 2026
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple MyelomaPHASE1 · RECRUITING · started Jan 23, 2024ClinicalTrials.gov NCT06153251 · fetched Nov 12, 2026
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i TherapiesPHASE3 · WITHDRAWN · started Jan 16, 2024ClinicalTrials.gov NCT06205290 · fetched Nov 12, 2026
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)PHASE1 · ACTIVE_NOT_RECRUITING · started Sep 13, 2023ClinicalTrials.gov NCT05869955 · fetched Nov 12, 2026
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple MyelomaPHASE1 · TERMINATED · started May 23, 2018ClinicalTrials.gov NCT03502577 · fetched Nov 12, 2026
Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple MyelomaPHASE1 · COMPLETED · started Nov 29, 2017ClinicalTrials.gov NCT03338972 · fetched Nov 12, 2026
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaPHASE1 · TERMINATED · started Nov 3, 2017ClinicalTrials.gov NCT03103971 · fetched Nov 12, 2026
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic MalignanciesPHASE1 · ACTIVE_NOT_RECRUITING · started Mar 15, 2017ClinicalTrials.gov NCT03085173 · fetched Nov 12, 2026
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple MyelomaPHASE1 · COMPLETED · started Feb 27, 2017ClinicalTrials.gov NCT03070327 · fetched Nov 12, 2026
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaPHASE1 · TERMINATED · started Nov 15, 2016ClinicalTrials.gov NCT02706405 · fetched Nov 12, 2026
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid TumorsPHASE1 · ACTIVE_NOT_RECRUITING · started Aug 1, 2015ClinicalTrials.gov NCT02498912 · fetched Nov 12, 2026